Congress moves to block drug makers' pay-for-delay deals

What it does

This bill prohibits brand-name drug and biologic manufacturers from paying generic drug makers and biosimilar manufacturers to delay market entry of cheaper alternatives. It treats such 'reverse payment' settlement agreements as unfair competition under the FTC Act, creates a legal presumption that these deals are anticompetitive, and allows the FTC to impose civil penalties up to three times the value received. The bill aims to preserve the competitive intent of the 1984 generic drug law and 2009 biosimilar law by blocking deals that keep cheaper drugs off the market longer than patent law requires.

Why we flagged it

The bill's core mechanism is a new FTC Act section creating a statutory prohibition and presumption against reverse payment settlements in pharmaceutical patent disputes. It is straightforward antitrust enforcement, not a subsidy, carve-out, or deregulation.

What the text implies

• The 30-day lookback window for 'related agreements' may capture legitimate ancillary deals (e.g., supply agreements, technology transfers) if they are contingent on or related to a patent settlement, potentially chilling legitimate business arrangements.
• The rebuttable presumption shifts burden to defendants to prove procompetitive benefits outweigh anticompetitive effects; while rebuttable, this inverts the usual antitrust burden and may increase litigation costs for smaller generic/biosimilar entrants defending their own settlements.

The full analysis lists 5 implications of this text.

Who stands to gain

Generic drug manufacturers (faster market entry, reduced pay-for-delay settlements); Biosimilar manufacturers (same competitive advantage); Public payers (Medicare, Medicaid, VA) and private insurers (lower drug costs)